

# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

Date: 29.05.2026

To,

The Head – Listing & Compliance  
National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,  
Bandra (E) Mumbai – 400 051

**Symbol : AMBEY**  
**ISIN : INE0M3I01029**

**Sub: Outcome of the Board Meeting held on 29<sup>th</sup> May 2026**

**Ref: Regulation 30 (read with Part A of Schedule III) and Regulation 33 and other applicable Regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), this is to inform you that the Board of Directors of the Company, at its meeting held today, i.e., on Friday, May 29, 2026, has considered and approved the following items:

**Audited Standalone and Consolidated Financial Results for the quarter, half year and financial year ended on March 31, 2026,**

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

1. Statements showing the audited standalone and consolidated financial results for the quarter, half-year and financial year ended March 31, 2026, along with the standalone and consolidated statements of assets and liabilities as at March 31, 2026, and the standalone and consolidated cash flow statements for the financial year ended March 31, 2026.
2. The Reports of the Statutory Auditors of the Company on the aforesaid Audited Standalone and Consolidated Financial Results;
3. Declaration pursuant to Regulation 33(3) (d) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. (“with unmodified opinion on the Audited Standalone and Consolidated Financial Results”).
4. Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc.
5. Disclosure of Related Party Transactions of the Company for the year ended March, 2026;

The Board Meeting commenced at 04:30 PM and concluded at 10:30 PM.

Kindly take the above information on record and oblige.

# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

Thanking You,

**For: DHANSA LABS LIMITED**

**Himanshu Kukreja**  
**Company Secretary**  
**Membership No: A64853**

**Enc: aa**

**DHANSALABS LIMITED**

(Formerly known as Ambey Laboratories Limited)

Regd. Office : Ground Floor, Property No.555 Tara Mohan, Ghisom, South West Delhi, Delhi, India, 110030

Corp. Office : B18/9, D/E Phase -I Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002

CIN: L74899DL1985PL003490 Email: info@ambeylab.com

**STANDALONE STATEMENT OF AUDITED FINANCIAL RESULTS  
FOR THE QUARTER, HALF YEAR ENDED AND YEAR ENDED 31 MARCH 2026**

Rs. In Lakhs

Sl. No	Particulars	Quarter ended			Half year ended		Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Income</b>							
	a) Revenue from operations	4,053.73	3,282.41	3,054.61	7,336.14	6,817.59	14,153.72	13,126.99
	b) Other income	107.91	30.03	86.23	137.94	13.37	151.30	191.61
	<b>Total income</b>	<b>4,161.64</b>	<b>3,312.44</b>	<b>3,140.83</b>	<b>7,474.08</b>	<b>6,830.96</b>	<b>14,305.02</b>	<b>13,318.60</b>
2	<b>Expenses</b>							
	a) Cost of material consumed	3,341.35	3,462.44	2,613.50	6,803.79	6,176.51	12,980.30	11,883.06
	b) Changes in inventories of work-in-progress, finished goods	402.68	(515.91)	68.64	(13.23)	(226.46)	8.18	(339.69)
	c) Employee benefits expense	13.12	23.65	60.75	38.77	77.01	115.78	174.99
	d) Finance costs	37.91	32.38	100.18	70.28	192.11	262.39	291.16
	e) Depreciation and amortisation expense	54.32	55.37	66.64	109.69	110.09	219.78	254.30
	f) Other expenses	63.90	40.81	76.77	104.71	201.13	305.83	294.59
	<b>Total expenses</b>	<b>3,913.28</b>	<b>3,109.74</b>	<b>2,986.48</b>	<b>7,014.01</b>	<b>6,530.39</b>	<b>13,544.39</b>	<b>12,714.77</b>
3	<b>Profit/(loss) before exceptional item &amp; tax (1-2)</b>	<b>248.36</b>	<b>211.70</b>	<b>154.35</b>	<b>460.06</b>	<b>300.57</b>	<b>760.63</b>	<b>603.83</b>
4	Exceptional items							
5	<b>Profit/(loss) before tax (3-4)</b>	<b>248.36</b>	<b>211.70</b>	<b>154.35</b>	<b>460.06</b>	<b>300.57</b>	<b>760.63</b>	<b>603.83</b>
6	<b>Tax expense</b>							
	Current tax	41.45	28.99	29.16	70.44	56.52	126.96	113.95
	Deferred tax charge/(benefit)	(40.32)	(2.82)	37.69	(43.14)	38.40	60.93	(47.44)
	-MAT credit entitlement	38.29	83.38	(29.16)	121.67	(56.52)	(57.66)	65.15
	<b>Tax expense</b>	<b>39.42</b>	<b>109.55</b>	<b>37.69</b>	<b>148.97</b>	<b>38.40</b>	<b>187.37</b>	<b>125.56</b>
7	<b>Net Profit/(Loss) after tax (5-6)</b>	<b>208.94</b>	<b>102.15</b>	<b>116.78</b>	<b>311.09</b>	<b>262.17</b>	<b>573.26</b>	<b>478.26</b>
8	<b>Paid-up Equity Share Capital (Face value of Rs.10/- each)</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>2,494.68</b>
9	Reserves (excluding retention reserve)						4,663.60	4,090.35
10	<b>Earnings per equity share (Nominal value per share Rs. 10) (not annualised, except year end)</b>							
	Basic earnings per share (in ₹)	0.84	0.41	0.47	1.25	1.05	2.30	2.06
	Diluted earnings per share (in ₹)	0.84	0.41	0.47	1.25	1.05	2.30	2.06

**Notes:-**

- The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 29 May 2026.
- The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard 'C' AS', prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Company has a single reportable segment as per the Accounting Standard - 17.
- The finance cost amount of the Company has been reduced by INR 58.94 lacs for the six months ended 31st March 2026. This reduction arises from the reversal of finance cost that had been recognised in the Statement of Profit and Loss for the six months ended 30th September 2025, which should have been capitalised in the books of account.

**For and on behalf of the Board of Directors of  
Dhansa Labs Limited  
(Formerly known as Ambey Laboratories Limited)**

**Archit Gupta**  
Whole Time Director  
DIN 00378409

Date: 29 May 2026  
Place: Gurugram

5	STANDALONE STATEMENT OF ASSETS & LIABILITIES		Rs. In Lakhs	
	Particulars	Standalone		
		As at 31.03.2026	As at 31.03.2025	
	<b>EQUITY AND LIABILITIES</b>			
<b>1</b>	<b>Shareholders' funds</b>			
	a) Share capital	2,494.68		2,494.68
	b) Reserves and surplus	5,713.60		5,140.35
	c) Money Received Against share warrant	1,697.53		-
	<b>Total Equity</b>	<b>9,905.81</b>		<b>7,635.03</b>
<b>2</b>	<b>Share Application Money Pending Allotment</b>	-		-
<b>3</b>	<b>Liabilities</b>			
	<b>Non-current liabilities</b>			
	a) Long-Term Borrowings	1,882.91		1,074.82
	b) Deferred tax liabilities	-		-
	c) Other long-term liabilities	-		-
	d) Long-term provisions	41.88		53.59
	<b>Total non-current liabilities</b>	<b>1,924.79</b>		<b>1,128.41</b>
	<b>Current liabilities</b>			
	a) Short-Term Borrowings	2,074.55		3,009.48
	b) Trade payables			
	(i) Total outstanding dues of micro enterprises and small enterprises; and	68.26		94.49
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	559.43		568.58
	c) Other current liabilities	273.29		192.75
	d) Short-term provisions	123.53		92.47
	<b>Total current liabilities</b>	<b>3,099.06</b>		<b>3,957.77</b>
	<b>Total equity and liabilities</b>	<b>14,929.66</b>		<b>12,721.21</b>
	<b>Assets</b>			
<b>1</b>	<b>Non-current assets</b>			
	a) Property, plant and equipment			
	(i) Property, plant and equipment	2,054.45		2,253.87
	(ii) Intangible assets	44.37		57.70
	(iii) Capital work-in-progress	2,203.83		1,566.42
	b) Non-current investments	10.00		-
	c) Deferred tax assets (Net)	146.80		142.07
	d) Long-term loans and advances	568.09		47.93
	e) Other non-current assets	-		-
	<b>Total non-current assets</b>	<b>5,027.54</b>		<b>4,068.00</b>
<b>2</b>	<b>Current assets</b>			
	a) Current investment	-		-
	b) Inventories	3,154.24		2,991.32
	c) Trade receivables	5,390.05		4,043.19
	d) Cash and bank balances	238.60		176.30
	e) Short-term loans and advances	624.25		788.35
	f) Other current assets	494.98		654.05
	<b>Total current assets</b>	<b>9,902.12</b>		<b>8,653.21</b>
	<b>Total assets</b>	<b>14,929.66</b>		<b>12,721.21</b>

**For and on behalf of the Board of Directors of**  
Dhansa Labs Limited  
(Formerly known as Ambey laboratories limited)

**Archit Gupta**  
Whole Time Director  
DIN 00378409

Date: 29 May 2026  
Place: Gurugram

6	STANDALONE STATEMENT OF CASH FLOWS	Rs. In Lakhs	
		For the year ended	
		31.03.2026	31.03.2025
<b>A. Cash flow from operating activities</b>			
Profit/(loss) before tax		760.63	603.83
Adjustments for :			
Depreciation and amortisation expense		219.78	254.30
Interest expense and finance cost		262.39	291.16
Unrealised foreign currency (gain)/loss		(51.68)	(2.43)
Loss on sale of fixed assets		(1.32)	0.71
Interest income		(28.72)	(14.97)
Gratuity and Leave Encashment Provision (Profit) & loss on sale of investment		(18.70)	20.54
		-	(11.09)
<b>Changes in assets and liabilities</b>		<b>1,142.38</b>	<b>1,142.04</b>
(Increase) / Decrease in inventories		(162.92)	(933.86)
(Increase) / Decrease in trade receivables		(1,295.18)	(2,171.93)
(Increase) / Decrease in short term loans and advances		164.10	(425.02)
(Increase) / Decrease in other assets		95.09	(144.11)
Increase / (decrease) in trade payables		(35.37)	(817.30)
Increase / (decrease) in other liabilities		96.89	14.80
<b>Cash generated from operating activities</b>		<b>4.99</b>	<b>(3,335.39)</b>
Taxes paid (net of refunds)		(104.84)	(112.85)
<b>Net cash generated from operating activities</b>		<b>(99.85)</b>	<b>(3,448.24)</b>
<b>B. Cash Flow from Investing Activities</b>			
(Purchase) Sale of Fixed Assets		(643.15)	(1,351.83)
Investment in subsidiary companies		(10.00)	-
Loan given		(485.04)	-
Investment in Fixed Deposit		2.06	(102.01)
Interest received		8.06	14.97
<b>Net cash generated from/(used in) investing activities</b>		<b>(1,128.07)</b>	<b>(1,349.66)</b>
<b>C. Cash flows from financing activities</b>			
Interest & Finance Cost		(278.74)	(291.16)
Proceeds from issues of equity shares		-	4,255.44
Expenses for initial public offer		-	(250.00)
Proceeds of long term borrowings		1,616.18	1,713.12
(Repayments) / proceeds of short term borrowings		(808.09)	(2,270.51)
Proceeds from issues of share warrants		(934.92)	1,677.27
		1,697.53	-
<b>Net cash generated from/(used in) financing activities</b>		<b>1,291.96</b>	<b>4,834.16</b>
<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>		<b>64.04</b>	<b>36.26</b>
Cash and cash equivalents at the beginning of year		72.76	36.50
<b>Cash and cash equivalents at the end of year</b>		<b>136.80</b>	<b>72.76</b>

The above statement of cash flow has been prepared under the 'Indirect Method'.

- 7 During the year ended 31 March 2026, the Holding Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the said warrants, the Holding Company has received Rs. 1,697.50 lakhs up to 31 March 2026 towards warrant subscription/part consideration. The warrants remain outstanding and pending conversion as at 31 March 2026.

The money received against these warrants has been utilized for the purposes detailed in the table below.

(Rs. in lacs unless otherwise stated)

Object of issue	Total issue size	Amount received till 31 March 2026	Amount utilized till 31 March 2026	Amount unutilized as on 31 March 2026	Deviation (if any)
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	4999.90	1697.50	1697.50	-	N/A
<b>Total</b>	4999.90	1697.50	1697.50	-	-

- 8 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, namely the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These Codes have become effective from November 21, 2025. The Ministry of Labour and Employment has issued draft Central Rules and related FAQs to facilitate assessment of the financial impact arising from the implementation of the New Labour Codes.

The Company has assessed the impact of the New Labour Codes and accounted for the incremental liability for its employees, to the extent ascertainable, in the financial statements for the year ended March 31, 2026. Accordingly, an incremental impact of Rs. 9.46 lakhs pertaining to gratuity and leave encashment has been recognised within employee benefit expenses. Further, the Company will continue to monitor the finalisation of Central/ State Rules, related clarifications and other developments in relation to the New Labour Codes and shall provide appropriate accounting effect for any further impact, as and when ascertainable.

- 9 The figures for the previous period have been regrouped / rearranged / reclassified wherever necessary.

**For and Behalf of Board of**  
Dhansa Labs Limited  
(Formerly known as Ambey Laboratories Limited)

**Archit Gupta**  
Whole Time Director  
DIN 00378409

Date: 29 May 2026  
Place: Gungram



F.R.N. 022743N

# KAPISH JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987  
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

**Independent Auditor's Report on the Audit of Standalone Financial Results of Dhansa Labs Limited (formerly known as Ambey Laboratories Limited) for the Quarter, Half Year and Year Ended 31 March 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To the Board of Directors of Dhansa Labs Limited**  
(formerly known as Ambey Laboratories Limited)

## **Report on the Audit of the Standalone Annual Financial Results**

### **Opinion**

We have audited the accompanying standalone financial results of **Dhansa Labs Limited (Formerly known as Ambey Laboratories Limited) ("the Company")** for the quarter, half year and year ended 31 March 2026 ("the Statement" or "standalone annual financial results"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the aforesaid Standalone Annual Financial Results:

- a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards specified under Section 133 of the Companies Act, 2013 ("the Act"), read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and other financial information of the Company for the quarter, half year ended and year ended 31 March 2026.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial results.



## **Management's and Board of Directors' Responsibilities for the Standalone Financial Results**

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management's and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/loss and other financial information in accordance with the recognition and measurement principles laid down in Accounting Standards (AS) prescribed under section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the company's financial reporting process.

## **Auditor's Responsibilities for the Audit of Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies



Act, 2013, we are also responsible for expressing our opinion on whether the company has internal financial controls with reference to Financial Statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Standalone Financial Results to express an opinion on the same.

Materiality is the magnitude of misstatements in the Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial results may be influenced. We consider quantitative materiality and qualitative factors in planning the scope of our audit work and in evaluating the results of our work, and to evaluate the effect of any identified misstatements in the Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matters**

- (1) During the FY 2025-26, the Company allotted 1,08,69,565 Convertible Equity Warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the said warrants, the Company has received Rs. 1,697.50 lakhs till 31 March 2026 towards warrant subscription/part consideration. The warrants remain outstanding and pending conversion as at 31 March 2026.



The money received against these warrants has been utilized for the purposes detailed in the table below.

(Rs. In Lakhs)

S.No.	Object of issue	Total issue size	Amount received till 31 March 2026	Amount utilized till 31 March 2026	Amount unutilized as on 31 March 2026	Deviation, if any
1.	The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure and land-related advances.	4,999.99	1,697.50	1,697.50	-	N/A
<b>Total</b>		<b>4,999.90</b>	<b>1,697.50</b>	<b>1,697.50</b>	<b>-</b>	<b>-</b>


- (2) The Standalone Financial Results include the results for the quarter ended 31 March 2026, being the balancing figure between the audited figures in respect of the full financial year ended 31 March 2026 and year-to-date figures up to the nine months ended 31 December 2025 which have been compiled by the Management from the books of account and other relevant records of the Company and were not subjected to limited review by us. Further, the figures for the half year ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2026 and the published unaudited figures for the half year ended 30 September 2025, which were subjected to limited review by us.

Our opinion on the standalone financial results is not modified in respect of the above matters.

**For Kapish Jain & Associates**

Chartered Accountants

Firm Registration No. 022743N



**CA Kapish Jain**

Partner

Membership No. 514162

UDIN: 26514162BZIJIG5207

Place: New Delhi

Date: 29 May 2026

**DHANSA LABS LIMITED**  
(Formerly known as Ambeey Laboratories Limited)  
Regd. Office : Ground Floor, Property No. 555 Taria Mohalla, Ghitori, South West Delhi, Delhi, India, 110030  
Corp. Office : B18/9, Dlf Phase -1 Sector 26A, Gurugram-122002, Gurugram, Haryana, India, 122002  
CIN: L74899DL1985PLC020490, Email: cs@ambeeylab.com

**CONSOLIDATED STATEMENT OF AUDITED FINANCIAL RESULTS  
FOR THE QUARTER, HALF YEAR ENDED AND YEAR ENDED 31 MARCH 2026**

Rs. In Lakhs

Sl. No	Particulars	Quarter ended			Half year ended		Year ended	
		31.03.2026	31.12.2025	31.03.2025	31.03.2026	30.09.2025	31.03.2026	31.03.2025
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)
1	<b>Income</b>							
	a) Revenue from operations	4,053.73	3,282.41	-	7,336.13	6,817.59	-	14,153.72
	b) Other income	87.86	30.03	-	117.99	13.37	-	130.96
	<b>Total Income</b>	<b>4,141.29</b>	<b>3,312.44</b>	<b>-</b>	<b>7,453.72</b>	<b>6,830.96</b>	<b>-</b>	<b>14,284.68</b>
2	<b>Expenses</b>							
	a) Cost of material consumed	3,341.35	3,462.44	-	6,803.79	6,176.51	-	12,980.30
	b) Changes in inventories of work-in-progress, finished goods	402.68	(515.91)	-	(113.23)	(226.46)	-	(339.69)
	c) Employee benefits expense	13.12	25.65	-	38.77	77.01	-	115.78
	d) Finance costs	37.91	32.37	-	70.28	192.11	-	262.39
	e) Depreciation and amortisation expense	54.32	55.38	-	109.69	110.09	-	219.78
	f) Other expenses	52.10	53.10	-	105.21	201.28	-	306.49
	<b>Total expenses</b>	<b>3,901.48</b>	<b>3,113.03</b>	<b>-</b>	<b>7,014.51</b>	<b>6,530.54</b>	<b>-</b>	<b>13,545.05</b>
3	<b>Profit/(loss) before exceptional item &amp; tax (1-2)</b>	<b>239.81</b>	<b>199.41</b>	<b>-</b>	<b>439.21</b>	<b>300.42</b>	<b>-</b>	<b>739.63</b>
4	Exceptional items	-	-	-	-	-	-	-
5	<b>Profit/(loss) before tax (3-4)</b>	<b>239.81</b>	<b>199.41</b>	<b>-</b>	<b>439.21</b>	<b>300.42</b>	<b>-</b>	<b>739.63</b>
6	Tax expense	-	-	-	-	-	-	-
	Current tax	41.45	28.99	-	70.44	56.52	-	126.96
	Deferred tax charge/(benefit)	(40.32)	(2.82)	-	(43.14)	38.40	-	(4.74)
	MAT credit entitlement	38.29	83.38	-	121.67	(56.52)	-	65.15
	<b>Tax expense</b>	<b>39.42</b>	<b>109.55</b>	<b>-</b>	<b>148.97</b>	<b>38.40</b>	<b>-</b>	<b>187.37</b>
7	<b>Net Profit/(Loss) after tax (5-6)</b>	<b>200.39</b>	<b>89.86</b>	<b>-</b>	<b>290.24</b>	<b>262.02</b>	<b>-</b>	<b>552.26</b>
8	<b>Paid-up Equity Share Capital (Face value of Rs.10/- each)</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>-</b>	<b>2,494.68</b>	<b>2,494.68</b>	<b>-</b>	<b>2,494.68</b>
9	Reserves (excluding revaluation reserve)	-	-	-	-	-	-	4,642.61
10	<b>Earnings per equity share</b>							
	[Nominal value per share Rs. 10] (not annualised, except year end)							
	Basic earnings per share (in ₹)	0.80	0.36	-	1.16	1.05	-	2.21
	Diluted earnings per share (in ₹)	0.80	0.36	-	1.16	1.05	-	2.21

**Notes:-**

- The above Financial Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on 29 May 2026.
- The above results have been prepared in accordance with the recognition and measurement principles of Accounting Standard ("AS"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- The Holding Company primarily engaged in the business of manufacturing and distribution of agro and home hygiene products. Hence, the Holding Company has a single reportable segment as per the Accounting Standard - 17.
- The finance cost amount of the Holding has been reduced by INR 58.94 lacs for the six months ended 31st March 2026. This reduction arises from the reversal of finance cost that had been recognised in the Statement of Profit and Loss for the six months ended 30th September 2025, which should have been capitalised in the books of account.

**For and Behalf of Board of**  
Dhansa Labs Limited  
(Formerly known as Ambeey Laboratories limited)

**Archit Gupta**  
Whole Time Director  
DIN 00378409

Date: 29 May 2026  
Place: Gurugram

5	CONSOLIDATED STATEMENT OF ASSETS & LIABILITIES	Rs. In Lakhs	
		Consolidated	
		As at 31.03.2026	As at 31.03.2025
	<b>Particulars</b>		
	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' funds</b>		
	a) Share capital	2,494.68	-
	b) Reserves and surplus	5,692.61	-
	c) Money Received Against share warrant	1,697.53	-
	<b>Total Equity</b>	<b>9,884.82</b>	<b>-</b>
<b>2</b>	<b>Share Application Money Pending Allotment</b>	-	-
<b>3</b>	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	a) Long-Term Borrowings	1,892.51	-
	b) Deferred tax liabilities	-	-
	c) Other long-term liabilities	-	-
	d) Long-term provisions	41.88	-
	<b>Total non-current liabilities</b>	<b>1,934.39</b>	<b>-</b>
	<b>Current liabilities</b>		
	a) Short-Term Borrowings	2,074.55	-
	b) Trade payables		
	(i) Total outstanding dues of micro enterprises and small	68.26	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	559.43	-
	c) Other current liabilities	446.69	-
	d) Short-term provisions	123.53	-
	<b>Total current liabilities</b>	<b>3,272.46</b>	<b>-</b>
	<b>Total equity and liabilities</b>	<b>15,091.67</b>	<b>-</b>
	<b>Assets</b>		
<b>1</b>	<b>Non-current assets</b>		
	a) Property, plant and equipment		
	(i) Property, plant and equipment	2,387.30	-
	(i) Intangible assets	44.37	-
	(iii) Capital work-in-progress	2,277.62	-
	b) Non-current investments	-	-
	c) Deferred tax assets (Net)	146.80	-
	d) Long-term loans and advances	114.75	-
	e) Other non-current assets	-	-
	<b>Total non-current assets</b>	<b>4,970.84</b>	<b>-</b>
<b>2</b>	<b>Current assets</b>		
	a) Current investment	-	-
	b) Inventories	3,154.24	-
	c) Trade receivables	5,390.05	-
	d) Cash and bank balances	249.64	-
	e) Short-term loans and advances	827.59	-
	f) Other current assets	499.31	-
	<b>Total current assets</b>	<b>10,120.83</b>	<b>-</b>
	<b>Total assets</b>	<b>15,091.67</b>	<b>-</b>
<p><b>For and Behalf of Board of</b>  Dhansa Labs Limited  (Formely known as Ambey laboratories limited)</p> <p><b>Archit Gupta</b>  Whole Time Director  DIN 00378409</p> <p>Date: 29 May 2026  Place: Gurugram</p>			

6 CONSOLIDATED STATEMENT OF CASH FLOWS		Rs. in Lakhs			
		For the year ended			
		31.03.2026	31.03.2025		
<b>A.</b>	<b>Cash flow from operating activities</b>				
	Profit/(loss) before tax	739.63	-		
	Adjustments for :				
	Depreciation and amortisation expense	219.78	-		
	Interest expense and finance cost	262.39	-		
	Unrealised foreign currency (gain)/loss	(51.68)	-		
	Loss on sale of fixed assets	(1.32)	-		
	Interest income	(8.38)	-		
	Consolidated adjustment	7,316.90	-		
	Gratuity and Leave Encashment Provision	(18.70)	-		
		<b>8,458.62</b>	-		
	<b>Changes in assets and liabilities</b>				
	(Increase) / Decrease in inventories	(3,154.24)	-		
	(Increase) / Decrease in trade receivables	(5,338.37)	-		
	(Increase) / Decrease in long term loans and advances	(1,14.75)	-		
	(Increase) / Decrease in short term loans and advances	(827.59)	-		
	(Increase) / Decrease in other assets	(499.31)	-		
	Increase / (decrease) in trade payables	627.70	-		
	Increase / (decrease) in long term provisions	60.58	-		
	Increase / (decrease) in other liabilities	446.69	-		
	<b>Cash generated from operating activities</b>	<b>(340.67)</b>	-		
	Taxes paid (net of refunds)	(96.13)	-		
	<b>Net cash generated from operating activities</b>	<b>(436.80)</b>	-		
<b>B.</b>	<b>Cash Flow from Investing Activities</b>				
	(Purchase) Sale of Fixed Assets	(4,927.75)	-		
	Investment in Fixed Deposit	101.80	-		
	Interest received	8.38	-		
	<b>Net cash generated from/used in investing activities</b>	<b>(4,817.57)</b>	-		
<b>C.</b>	<b>Cash flows from financing activities</b>				
	Interest & Finance Cost	(262.39)	-		
	(Repayments) of long term borrowings	1,892.51	-		
	(Repayments) / proceeds of short term borrowings	2,074.55	-		
	Proceeds from issues of share warrants	1,697.53	-		
	<b>Net cash generated from/used in financing activities</b>	<b>5,402.20</b>	-		
	<b>Net increase/(decrease) in cash and cash equivalents (A+B+C)</b>	<b>147.83</b>	-		
	Cash and cash equivalents at the beginning of year	-	-		
	<b>Cash and cash equivalents at the end of year</b>	<b>147.83</b>	-		
The above statement of cash flow has been prepared under the Indirect Method.					
7 During the year ended 31 March 2026, the Holding Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.					
Against the said warrants, the Holding Company has received Rs. 1,697.50 lakhs up to 31 March 2026 towards warrant subscription/part consideration. The warrants remain outstanding and pending conversion as at 31 March 2026.					
The money received against these warrants has been utilized for the purposes detailed in the table below.					
(Rs. in lacs unless otherwise stated)					
<b>Object of issue</b>	<b>Total issue size</b>	<b>Amount received till 31 March 2026</b>	<b>Amount utilized till 31 March 2026</b>	<b>Amount unutilized as on 31 March 2026</b>	<b>Deviation (if any)</b>
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure, and land-related advances.	899.90	1697.50	1697.50	-	N/A
<b>Total</b>	<b>899.90</b>	<b>1697.50</b>	<b>1697.50</b>	<b>-</b>	<b>N/A</b>
8 The Consolidated financial results for the quarter, half-year and year ended on 31 March 2026 includes the following entities of the Group :					
<b>S.no.</b>	<b>Name of the entity</b>	<b>Relation</b>			
1	Dhansa Green Energy Private Limited (w.e.f. 14 August 2025)	Subsidiary Company			
2	Dhansa Biofuels Power Private Limited (w.e.f. 27 January 2026) *	Subsidiary Company			
* Dhansa Biofuels Power Private Limited was incorporated during the year as a wholly owned subsidiary of the Holding Company; however, it had not commenced its business operations up to 31 March 2026.					
9 The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, namely the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These Codes have become effective from November 21, 2025. The Ministry of Labour and Employment has issued draft Central Rules and related FAQs to facilitate assessment of the financial impact arising from the implementation of the New Labour Codes.					
The Holding company has assessed the impact of the New Labour Codes and accounted for the incremental liability for its employees, to the extent ascertainable, in the financial statements for the year ended March 31, 2026. Accordingly, an incremental impact of Rs. 9.46 lakhs pertaining to gratuity and leave encashment has been recognised within employee benefit expenses. Further, the Holding company will continue to monitor the finalisation of Central State Rules, related clarifications and other developments in relation to the New Labour Codes and shall provide appropriate accounting effect for any further impact, as and when ascertainable.					
10 The Consolidated Financial Results include the results for the quarter ended 31 March 2026, being the balancing figure between the audited figures in respect of the full financial year ended 31 March 2026 and year-to-date figures up to the nine months ended 31 December 2025 which have been compiled by the Management from the books of account and other relevant records of the Company and were not subjected to limited review by us. Further, the figures for the half year ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2026 and the published unaudited figures for the half year ended 30 September 2025, which were subjected to limited review by us.					
11 The figures for the previous period have been regrouped/ rearranged/ reclassified wherever necessary.					
<b>For and Behalf of Board of</b> Dhansa Labs Limited (Formerly known as Ambeey Laboratories Limited)					
<b>Archit Gupta</b> Whole Time Director DIN 00378409					
Date: 29 May 2026 Place: Gurugram					



F.R.N. 022743N

# KAPISH JAIN & ASSOCIATES

## CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987  
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

### Independent Auditor's Report on the Audit of Consolidated Financial Results of Dhansa Labs Limited (formerly known as Ambey Laboratories Limited) for the Quarter, Half Year and Year Ended 31 March 2026 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Dhansa Labs Limited  
(Formerly known as Ambey Laboratories Limited)

#### Report on the Audit of the Consolidated Annual Financial Results

#### Opinion

We have audited the accompanying statement of Consolidated Audited Financial Results of **Dhansa Labs Limited (Formerly known as Ambey Laboratories Limited)** ("the Holding Company") and its subsidiary, the Holding Company and its subsidiary together referred to as "the Group" for the quarter and half year ended and year ended 31 March 2026 ("the Statement" or "consolidated annual financial results"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of independent auditors on separate audited financial statements of the subsidiary, the aforesaid consolidated annual financial results:

- a. include the results of the following entity:

S.no.	Name of the entity	Relation
1	Dhansa Green Energy Private Limited (w.e.f. 14 August 2025)	Subsidiary Company
2	Dhansa Biofuels Power Private Limited (w.e.f. 27 January 2026) *	Subsidiary Company

*\*Dhansa Biofuels Power Private Limited was incorporated during the year as a wholly owned subsidiary of the Holding Company; however, it had not commenced its business operations up to 31 March 2026.*

- b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Accounting Standards, and other accounting principles generally accepted in India, of the consolidated net profit and other financial information of the Group for the quarter and half year ended and year ended 31 March 2026.



## **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (“SAs”) specified under section 143(10) of the Companies Act, 2013 (“the Act”). Our responsibilities under those Standards are further described in the Auditor’s Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, together with the audited financial statements of the subsidiary considered for the purpose of consolidation, is sufficient and appropriate to provide a basis for our opinion on the Consolidated Financial Results.

## **Management’s and Board of Directors’ Responsibilities for the Consolidated Annual Financial Results**

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company’s Management and Board of Directors are responsible for the preparation and presentation of the Consolidated Financial Results that give a true and fair view of the consolidated net profit/loss and other financial information of the Group in accordance with the recognition and measurement principles laid down in the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (“the Act”), read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations.

The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of their respective companies and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records relevant to the preparation and presentation of the Consolidated Financial Results that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Consolidated Financial Results by the Management and Board of Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Annual Results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of their respective companies.



## **Auditor's Responsibilities for the Audit of Consolidated Annual Financial Results**

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Holding Company and its subsidiary company have adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the management and Board of Directors.
- Conclude on the appropriateness of Management and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the consolidated annual financial results of which we are the independent auditors. For the other entities included in the consolidated annual financial results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.



We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

### Other Matters

- (1) The Consolidated Financial Results includes audited financial results/information of one subsidiary namely Dhansa Green Energy Private Limited, whose financial statements reflect total assets of Rs.162.01 Lakhs as at 31 March 2026, total revenues of Rs. Nil Lakhs, Rs. Nil Lakhs and Rs. Nil Lakhs for the quarter ended 31 March 2026, half year ended 31 March 2026 and year ended 31 March 2026 respectively, total net profit / (loss) after tax of Rs. (8.55) Lakhs, Rs. (20.85) and Rs. (21.00) Lakhs for the quarter ended 31 March 2026, half year ended 31 March 2026 and year ended 31 March 2026 respectively and net cash inflows / (outflow) of Rs. 83.79 Lakhs for the year ended 31 March 2026, as considered in the Consolidated Financial Results, which have been audited by their independent auditor.

The independent auditor's report on the financial results of above entity has been furnished to us by the management and our opinion on the Consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of said subsidiary, is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

Our opinion on the Consolidated Financial Results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

- (2) The Holding Company acquired 100% stake in M/s Dhansa Green Energy Private Limited with effect from 14 August 2025. As a result, the consolidated figures for the quarter ended 31 March, 2026 and six-months ended 30 September 2025, include subsidiary's financials from that date onward. Consequently, comparative figures for the quarter, six months and year ended on 31 March 2025, are not presented in these results, as subsidiary company was not part of the group during those periods.
- (3) The Holding Company incorporated another wholly owned subsidiary company named M/s Dhansa Biofuels Power Private Limited with effect from 27 January 2026. However, as informed by the Management, the commercial activity of the said subsidiary had not commenced up to 31 March 2026 and hence there was no revenue from the said subsidiary during the year ended 31 March 2026.

Accordingly, no financial working / financial information of the said subsidiary has been considered in the consolidation process for the year ended 31 March 2026.



- (4) During the year ended 31 March 2026, the Holding Company allotted 1,08,69,565 convertible equity warrants on preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 lakhs, in accordance with Section 42 and Section 62(1)(c) of the Companies Act, 2013 and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the said warrants, the Holding Company has received Rs. 1,697.50 lakhs up to 31 March 2026 towards warrant subscription/part consideration. The warrants remain outstanding and pending conversion as at 31 March 2026.

The money received against these warrants has been utilized for the purposes detailed in the table below.

(Rs. In Lakhs)

S.No.	Object of issue	Total issue size	Amount received up to 31 March 2026	Amount utilized up to 31 March 2026	Amount unutilized up to 31 March 2026	Deviation, if any
1.	The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure and land-related advances.	4,999.99	1,697.50	1,697.50	-	N/A
Total		4,999.90	1,697.50	1,697.50	-	-

- (5) The Consolidated Financial Results include the results for the quarter ended 31 March 2026, being the balancing figure between the audited figures in respect of the full financial year ended 31 March 2026 and year-to-date figures up to the nine months ended 31 December 2025 which have been compiled by the Management from the books of account and other relevant records of the Company and were not subjected to limited review by us. Further, the figures for the half year ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year ended 31 March 2026 and the published unaudited figures for the half year ended 30 September 2025, which were subjected to limited review by us.

Our opinion on the consolidated annual financial results is not modified in respect of the above matters.

**For Kapish Jain & Associates**

Chartered Accountants

Firm Registration Number 022743N

  
CA Kapish Jain

Partner

Membership No. 514162

UDIN: 26514162VXVZSJ7487

Place: New Delhi

Date: 29 May 2026



# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,

GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

Date: 29.05.2026

To,

The Head – Listing & Compliance  
National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400 051

Symbol: AMBEY

ISIN : INE0M3I01029

**Sub: Declaration pursuant to Regulation 33(3) (d) of the Securities & Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015**

**Ref: SEBI circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016**

In Compliance with Regulation 33(3) (d) of LODR as amended by SEBI circular No. CIR/CFD/CMD/56/2016 dated May 27, 2016 we hereby declare that, Statutory Auditors of our Company M/s Kapish Jain & Associates, Chartered Accountants (Membership No. 514162) have issued an Audit Report with unmodified opinion on the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter, half year and financial year ended 31<sup>st</sup> March, 2026.

Kindly take the above information on record and oblige.

Thanking You,

For: **DHANSA LABS LIMITED**



Sarvar Alam

Designation: Chief Financial Officer

# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

## **Statement of Deviation/Variation in the utilization of funds raised**

**Amount in Lakhs**

Name of listed entity	Dhansa Labs Limited (Formerly known as Ambey Laboratories Limited)
Mode of Fundraising	Preferential Issue
Date of Raising Funds	14 <sup>th</sup> August, 2025 & 19 <sup>th</sup> August, 2025
Amount Raised	Rs. 1697.50/-
Report filed for the Half Year ended	31 <sup>st</sup> March, 2026
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If Yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	Not Applicable
If Yes, Date of shareholder Approval	Not Applicable
Explanation for the Deviation/Variation	Not Applicable
Comments of the Audit Committee after review	Not Applicable
Comments of the auditor, if any	Not Applicable

Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund-raising document i.e., letter of offer, etc

# Dhansa Labs Limited

Formerly known as Ambey Laboratories Limited

CIN: L74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

---

Original Object	Modified Objective if any	Original Allocation	Modified allocation, if any	Funds Utilized	Amount of Deviation/Variation for the according quarter to applicable object	Remark if any
The funds were utilised towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure; and land-related advances.	Not Applicable	4999.99	Not Applicable	1697.50	Not Applicable	None
<b>Total</b>		<b>4999.99</b>		<b>1697.50</b>		

**Kindly take the above information for your records.**

**For: DHANSA LABS LIMITED**

**Himanshu Kukreja**  
**Company Secretary**  
**Membership No: A64853**



F.R.N. 022743N

# KAPISH JAIN & ASSOCIATES

## CHARTERED ACCOUNTANTS

Head Office: 504, B-Wing, Statesman House, 148, Barakhamba Road, New Delhi - 110001 | Phone : +91-11-43708987  
Mobile : +91 9971 921466 | Email : ca.kapish@gmail.com | Website : www.kapishjainassociates.com; www.cakja.com

### WARRANT FUND UTILISATION CERTIFICATE

To,  
The Board of Directors  
Dhansa Labs Limited  
(Formerly known as Ambey Laboratories Limited)  
Ground Floor, Property No. 555, Tarla Mohalla,  
Ghitorni, South West Delhi – 110 030, India

We, M/s Kapish Jain & Associates, Chartered Accountants (FRN: 022743N), are the Statutory Auditors of the Company. We hereby certify that **Dhansa Labs Limited** (formerly known as Ambey Laboratories Limited) has allotted 1,08,69,565 convertible equity warrants on a preferential basis at an issue price of Rs. 46/- per warrant, aggregating to Rs. 4,999.99 Lakhs (Rupees Forty-Nine Crore Ninety-Nine Lakh Ninety-Nine Thousand Only), in accordance with the provisions of Section 42 and Section 62(1)(c) of the Companies Act, 2013, and applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Against the said warrants, the Company has received Rs. 1,697.50 Lakhs (Rupees Sixteen Crore Ninety-Seven Lakh Fifty Thousand Only) as on 31st March, 2026 towards warrant subscription / part consideration.

Based on the information and documents provided to us, the fund utilisation status as on **31st March, 2026** is as under:

(Rs. In Lakhs)

S. No.	Object of Issue	Total Issue Size	Amount Received till 31 March 2026	Amount Utilized till 31 March 2026	Amount Unutilized as on 31 March 2026	Deviation, if any
1.	The funds were utilized towards general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure and land-related advances.	4,999.99	1,697.50	1,697.50	–	N/A
	<b>Total</b>	<b>4,999.99</b>	<b>1,697.50</b>	<b>1,697.50</b>	<b>–</b>	<b>–</b>

This certificate is issued on the request of the management of the Company for the purpose of uploading the documents on the NSE / SEBI site as per the applicable SEBI Regulations, including Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Yours faithfully,

For **Kapish Jain & Associates**  
**Chartered Accountants**

Firm Reg. No.: 022743N

  
CA **Kapish Jain**  
Partner



Membership No.: 514162

UDIN: 26514162XCUZTR9787

Place: New Delhi

Date: 29 May 2026

